This Day On The Street
Continue to site right-arrow
ADVERTISEMENT
This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration.
Need a new registration confirmation email? Click here
TheStreet Open House

Biostar: Best Small-Cap Pharma Stock

And the most significant reason for overhang on the shares comes from the company's recent conference call. In response to an investor question, the company responded that they did not rule out the possibility of issuing equity in 2010 in case any potential acquisitions came up. This has put a temporary cap on the stock price which creates a tremendous buying opportunity. After speaking with the CFO I decided to invest in Biostar, strongly betting that they will not issue equity in the near term or at these current depressed prices. First, the company is on the verge of uplisting. It should very soon be able to issue equity in the $8-10 range, not in the $4 range.

An equity issuance would clearly hinder the uplisting and management would be unlikely to do this no matter how attractive the acquisition. Second, I confirmed with the CFO Elaine Zhao that the company has adequate working capital to operate the business without raising any money at all, and the only reason to raise money would be if an acquisition came along. Third, Biostar just completed an acquisition which they are currently in the process of integrating. It would not make sense for the company to feel compelled to issue equity at very depressed prices to rush into another acquisition before the first one was fully integrated. Finally, in speaking with the CFO it is clear that the company does not have any acquisition targets currently identified. In other words, this current overhang is likely unjustified and creates a great buying opportunity. Had the company been clearer on this issue on the conference call, I think the stock would have rebounded strongly and would now be in the $4.50-$5 range.

The reason I bought Biostar is that once the share price stabilizes above $4 the uplisting should come quickly. In fact the $4 level is somewhat of a self fulfilling prophecy for the uplisting. To be specific, Nasdaq requires a closing BID price above $4 for seven consecutive days, it is not based off of the closing price. I spoke with the CFO and she confirmed that Biostar has already applied for listing and meets all of the corporate governance requirements including having the required number of independent board members. Once it trades on the Nasdaq, I would expect Biostar to trade on a P/E of at least 10x vs. 2010 numbers. Earnings for 2010 are projected at $18 million to $20 million. In the short term, I think a price of $8-$10 is more likely. That is a return profile roughly equivalent to how Wuxi has done over the past year, and is not unachievable. In the meantime, buying Biostar at prices below $5 is a gift that will not likely last very long.

3 of 4

Check Out Our Best Services for Investors

Action Alerts PLUS

Portfolio Manager Jim Cramer and Director of Research Jack Mohr reveal their investment tactics while giving advanced notice before every trade.

Product Features:
  • $2.5+ million portfolio
  • Large-cap and dividend focus
  • Intraday trade alerts from Cramer
Quant Ratings

Access the tool that DOMINATES the Russell 2000 and the S&P 500.

Product Features:
  • Buy, hold, or sell recommendations for over 4,300 stocks
  • Unlimited research reports on your favorite stocks
  • A custom stock screener
Stocks Under $10

David Peltier uncovers low dollar stocks with serious upside potential that are flying under Wall Street's radar.

Product Features:
  • Model portfolio
  • Stocks trading below $10
  • Intraday trade alerts
14-Days Free
Try it NOW
Only $9.95
Try it NOW
14-Days Free
Try it NOW

Check Out Our Best Services for Investors

Dividend Stock Advisor

David Peltier identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.

Product Features:
  • Diversified model portfolio of dividend stocks
  • Updates with exact steps to take - BUY, HOLD, SELL
Trifecta Stocks

Every recommendation goes through 3 layers of intense scrutiny—quantitative, fundamental and technical analysis—to maximize profit potential and minimize risk.

Product Features:
  • Model Portfolio
  • Intra Day Trade alerts
  • Access to Quant Ratings
Options Profits

Our options trading pros provide over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.

Product Features:
  • Actionable options commentary and news
  • Real-time trading community
Try it NOW
Try it NOW
Try it NOW
To begin commenting right away, you can log in below using your Disqus, Facebook, Twitter, OpenID or Yahoo login credentials. Alternatively, you can post a comment as a "guest" just by entering an email address. Your use of the commenting tool is subject to multiple terms of service/use and privacy policies - see here for more details.
Submit an article to us!
SYM TRADE IT LAST %CHG
BMY $65.00 0.46%
BSPM $1.24 4.20%
LLY $73.44 -1.24%
MRK $57.60 -1.13%
TPI $0.47 14.00%

Markets

DOW 17,678.23 -40.31 -0.23%
S&P 500 2,056.15 -4.90 -0.24%
NASDAQ 4,863.3620 -13.1570 -0.27%

Partners Compare Online Brokers

Free Reports

Free Newsletters from TheStreet

My Subscriptions:

After the Bell

Before the Bell

Booyah! Newsletter

Midday Bell

TheStreet Top 10 Stories

Winners & Losers

Register for Newsletters
Top Rated Stocks Top Rated Funds Top Rated ETFs